Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.

Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J. 2009 Dec; 158(6):998-1004.e1.

View in: PubMed

subject areas

Aged
Angioplasty, Balloon, Coronary
Double-Blind Method
Feasibility Studies
Female
Humans
Injections, Intravenous
Male
Middle Aged
Myocardial Infarction
Pharmaceutical Preparations
Pilot Projects
Platelet Aggregation Inhibitors
Purinergic P2 Receptor Antagonists
Receptors, Purinergic P2Y12

authors with profiles

Robert Harrington